Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3
NCT05541107Phase 3Unknown
- Sponsor
- Matinas BioPharma
- Start
- Jan 2023
- Primary completion
- Oct 2024
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
A Phase 3 trial of MAT2203 in cryptococcal meningitis, sponsored by Matinas BioPharma. Status: unknown.
02
Drugs
MAT2203
03
Conditions
cryptococcal meningitis
Beyond the preview
Go deeper on NCT05541107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05541107.